首页工具

Anticancer agent 42

产品编号 T61777 CAS 2687265-18-3

Anticancer agent 42 (compound 10d) is an orally active, potent anticancer agent with demonstrated efficacy against MDA-MB-231 cells, exhibiting an IC50 of 0.07 μM. It exerts its anticancer activity through the activation of apoptotic pathways and p53 expression. Anticancer agent 42 is a valuable tool for investigating metastatic breast cancer [1].

TargetMol的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

Anticancer agent 42, CAS 2687265-18-3

规格	价格/CNY	货期
25 mg	￥ 10,600	6-8周
50 mg	￥ 13,800	6-8周
100 mg	￥ 17,500	6-8周

大包装超大折扣，点击咨询

该分子属于定制产品。陶术拥有优秀的合成团队，经验和能力，可以为您提供高性价比的产品。但由于客观因素，研发中会存在小概率合成不成功的情况，还请理解，如您有任何问题，欢迎咨询，我们将竭诚为您服务。

更多批次查询请联系客服

生物活性

化学信息

存储 & 溶解度

产品描述	Anticancer agent 42 (compound 10d) is an orally active, potent anticancer agent with demonstrated efficacy against MDA-MB-231 cells, exhibiting an IC50 of 0.07 μM. It exerts its anticancer activity through the activation of apoptotic pathways and p53 expression. Anticancer agent 42 is a valuable tool for investigating metastatic breast cancer [1].
体外活性	Anticancer agent 42 (compound 10d) (0-20 μM, 4 h) exhibits a potent antitumor activity against MDA-MB-231 cells [1]. Anticancer agent 42 (10 μM, 24 h) induces G2 and S phase arrest in MDA-MB-231 cells [1]. Anticancer agent 42 (10 μM, 24 h) induces cell apoptosis by regulating the expression of apoptosis related proteins in MDA-MB-231 cells [1]. Anticancer agent 42 (0-1 μM) depolarizes mitochondrial membrane and decreases the mitochondrial membrane potential leading to apoptosis [1]. Anticancer agent 42 (0-1 μM, 24 h) induces the cells to produce a large amount of ROS [1]. Cell Viability Assay Cell Line: A549, MDA-MB-231, HeLa [1] Concentration: 0-20 μM Incubation Time: 4 h Result: Exhibited a potent activity against MDA-MB-231 with an IC 50 of 0.07 μM. Cell Cycle Analysis Cell Line: MDA-MB-231 cells [1] Concentration: 10 μM Incubation Time: 24 h Result: Induced G2 and S phase arrest in MDA-MB-231 cells; caused the percentage of MDA-MB-231 cells in G1 phase to decrease significantly (from 74.44% to 16.48%), cells in G1 phase to increase (from 16.61% to 28.47%), and in G2 phase to significantly increase (from 8.95% to 55.05%). Apoptosis Analysis Cell Line: MDA-MB-231 cells [1] Concentration: 10 μM Incubation Time: 24 h Result: Induced cell apoptosis, with apoptotic rate of 31.69%. Western Blot Analysis Cell Line: MDA-MB-231 cells [1] Concentration: 100 nM Incubation Time: 48 h Result: Increased the level of human apoptosis-related proteins (pro-caspase 3, catalase, HTRA2/Omi and p53) in MDA-MB-231 cell. Western Blot Analysis Cell Line: MDA-MB-231 cells [1] Concentration: 0, 0.035, 0.07, 0.14, 0.21 μM Incubation Time: 24 h Result: Increased caspase 9, caspase3, cytochrome C and Bax expression, but decreased Bal-2 expression with increasing concentration.
体内活性	Anticancer agent 42 (compound 10d) (Kunming mice, 5000 mg/kg, Intragastric administration, once) has extremely low oral toxicity [1]. Anticancer agent 42 (Kunming mice, 238-600 mg/kg, IP, once) shows no obvious liver and kidney damage to mice, with an LD 50 of 374 mg/kg [1]. Anticancer agent 42 (Kunming mice, 25 mg/kg, IP, once every two days) causes mild liver and kidney damage [1]. Anticancer agent 42 (BALB/c mice, suppresses breast cancer 4T1 tumor growth, the anti-tumor effect is better combined use with CA (Cyanoacrylates), and can cross through the skin to achieve anti-tumor effects. [1]. Animal Model: Kunming mice (n=10, 5 male and 5 female) [1] Dosage: 5000 mg/kg Administration: Intragastric administration, once Result: Had extremely low oral toxicity, did not cause death in mice at 5000 mg/kg. Animal Model: Kunming mice [1] Dosage: 600, 476, 378, 300, 238 mg/kg Administration: IP, once Result: Showed no obvious liver and kidney damage to mice, with an LD 50 of 374 mg/kg. Animal Model: Kunming mice (n=3) [1] Dosage: 25 mg/kg Administration: IP, once every two days Result: Caused mild liver and kidney damage after administration, slightly increased ALT, AST and BUN of mice. Animal Model: BALB/c mice (4T1 tumor-bearing, female, eight groups, 6 mice per group) [1] Dosage: 10d (50 mg/kg) + CA; 10d (50 mg/kg) + saline; 10d (200 mg/kg) + CA Administration: Intratumoral injection, every four days (50 mg/kg); smear, every two days (200 mg/kg), for 14 days. Result: Showed obvious antitumor effect from the 8th day; had protective effects on the spleens of tumor-bearing mice; the anti-tumor effect is better when combined use with CA; can cross through the skin to achieve anti-tumor effects.

分子量	391.25
分子式	C19H16Cl2N2O3
CAS No.	2687265-18-3

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

计算器

摩尔浓度计算器

稀释计算器

配液计算器

分子量计算器

质量

浓度

容积

分子量

浓度 (起始)

容积 (起始)

浓度 (终)

容积 (终)

溶液体积

质量

配液浓度

剂量换算

对于不同动物的给药剂量换算，您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300，混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。

第一步：请输入动物实验的基本信息

剂量

mg/kg

每只动物体重

给药体积

μL

动物数量

第二步：请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。

% DMSO+

% +